↓ Skip to main content

Dove Medical Press

Article Metrics

Emerging pharmaceutical therapies for COPD

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, July 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
46 Mendeley
Title
Emerging pharmaceutical therapies for COPD
Published in
International Journal of Chronic Obstructive Pulmonary Disease, July 2017
DOI 10.2147/copd.s121416
Pubmed ID
Authors

Sowmya Lakshmi, Aravind Reddy, Raju Reddy

Abstract

COPD, for which cigarette smoking is the major risk factor, remains a worldwide burden. Current therapies provide only limited short-term benefit and fail to halt progression. A variety of potential therapeutic targets are currently being investigated, including COPD-related proinflammatory mediators and signaling pathways. Other investigational compounds target specific aspects or complications of COPD such as mucus hypersecretion and pulmonary hypertension. Although many candidate therapies have shown no significant effects, other emerging therapies have improved lung function, pulmonary hypertension, glucocorticoid sensitivity, and/or the frequency of exacerbations. Among these are compounds that inhibit the CXCR2 receptor, mitogen-activated protein kinase/Src kinase, myristoylated alanine-rich C kinase substrate, selectins, and the endothelin receptor. Activation of certain transcription factors may also be relevant, as a large retrospective cohort study of COPD patients with diabetes found that the peroxisome proliferator-activated receptor γ (PPARγ) agonists rosiglitazone and pioglitazone were associated with reduced COPD exacerbation rate. Notably, several therapies have shown efficacy only in identifiable subgroups of COPD patients, suggesting that subgroup identification may become more important in future treatment strategies. This review summarizes the status of emerging therapeutic pharmaceuticals for COPD and highlights those that appear most promising.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 46 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 20%
Student > Master 6 13%
Student > Bachelor 6 13%
Other 5 11%
Researcher 5 11%
Other 7 15%
Unknown 8 17%
Readers by discipline Count As %
Medicine and Dentistry 14 30%
Pharmacology, Toxicology and Pharmaceutical Science 7 15%
Biochemistry, Genetics and Molecular Biology 5 11%
Immunology and Microbiology 3 7%
Agricultural and Biological Sciences 2 4%
Other 3 7%
Unknown 12 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 October 2020.
All research outputs
#4,833,023
of 16,614,363 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#608
of 1,924 outputs
Outputs of similar age
#90,270
of 273,735 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#24
of 61 outputs
Altmetric has tracked 16,614,363 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 1,924 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,735 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 61 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.